About meiragtx holdings plc - MGTX
MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It targets local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet needs. The company was founded on March 20, 2015 and is headquartered in New York, NY.
MGTX At a Glance
MeiraGTx Holdings Plc
655 Third Avenue
New York, New York 10017
| Phone | 1-646-860-7985 | Revenue | 81.39M | |
| Industry | Biotechnology | Net Income | -114,201,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 144.572% | |
| Fiscal Year-end | 12 / 2026 | Employees | 403 | |
| View SEC Filings |
MGTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.856 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.983 |
| Enterprise Value to Sales | 8.136 |
| Total Debt to Enterprise Value | 0.134 |
MGTX Efficiency
| Revenue/Employee | 201,962.779 |
| Income Per Employee | -283,377.171 |
| Receivables Turnover | 4.451 |
| Total Asset Turnover | 0.313 |
MGTX Liquidity
| Current Ratio | 0.749 |
| Quick Ratio | 0.749 |
| Cash Ratio | 0.538 |
MGTX Profitability
| Gross Margin | 78.64 |
| Operating Margin | -131.916 |
| Pretax Margin | -140.312 |
| Net Margin | -140.312 |
| Return on Assets | -43.857 |
| Return on Equity | -368.188 |
| Return on Total Capital | -137.769 |
| Return on Invested Capital | -112.002 |
MGTX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 106.989 |
| Total Debt to Total Assets | 35.327 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 73.769 |